IO Biotech News

News

Ticker

IOBT

ISIN

US4497781090

Chiffre d'affaires Résultat net P/E P/S EBIT Dividende Achats de membres du conseil Actions Capitalisation boursière Endettement Passifs Capitaux propres AAQS Effectifs ROE ROA ROCE News Documents

Actualités Eulerpool IO Biotech

Actualités de l'action IO Biotech

IO Biotech est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant IO Biotech.

13 février·
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
6 février·
ChartMill
Curious about the stocks that are showing activity after the closing bell on Friday?
26 janvier·
Benzinga
IO Biotech shares are trading lower after Piper Sandler downgraded the stock from Overweight to Neutral and cut its price target from $3 to $0.5.
21 janvier·
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
21 janvier·
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
21 janvier·
Yahoo
IO Biotech Announces Exploration of Strategic Alternatives
20 janvier·
Yahoo
Moderna cancer vaccine holds up; IO Biotech considers a sale
15 décembre·
Yahoo
IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
27 novembre·
SeekingAlpha
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
14 novembre·
Yahoo
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
7 novembre·
Yahoo
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
20 octobre·
Yahoo
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
30 septembre·
Yahoo
IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says
29 septembre·
Benzinga
Crude Oil Falls Sharply; Carnival Posts Upbeat Earnings
23 septembre·
Benzinga
IO Biotech To Present Phase 3 And Final Phase 2 Trial Results For IO102-IO103 Cancer Vaccine Plus Pembrolizumab At 2025 ESMO Congress
9 septembre·
SeekingAlpha
IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
26 août·
Yahoo
H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14
15 août·
Benzinga
IO Biotech shares are trading higher following the release of its Q2 financial results.
12 août·
SeekingAlpha
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma
11 août·
Yahoo
IO Biotech to pursue cancer vaccine approval despite Phase III miss

Communiqués de presse relatifs à l'action IO Biotech

IO Biotech publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

IO Biotech News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action IO Biotech (IOBT, ISIN : US4497781090). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez IO Biotech.

IO Biotech Action

IO Biotech IO Biotech Inc, based in Copenhagen, Denmark, operates in the Health Care sector, specializing in Biotechnology. The company develops immune modulating cancer therapies using its T-win technology platform, focusing on disrupting tumor-induced immunosuppression. Its lead product candidate, IO102-IO103, targets immunosuppressive proteins like IDO and PD-L1. Founded as a spin-off from the National Cancer Center Immune Therapy at Herlev University Hospital, IO Biotech has 57 employees and is listed on the stock exchange since November 5, 2021.